Leerink Partnrs Has Strong Estimate for Icon FY2025 Earnings

Icon Plc (NASDAQ:ICLR - Free Report) - Stock analysts at Leerink Partnrs boosted their FY2025 EPS estimates for shares of Icon in a research report issued to clients and investors on Tuesday, July 8th. Leerink Partnrs analyst M. Cherny now expects that the medical research company will post earnings of $12.68 per share for the year, up from their previous forecast of $12.66. The consensus estimate for Icon's current full-year earnings is $13.38 per share. Leerink Partnrs also issued estimates for Icon's FY2026 earnings at $13.54 EPS and FY2027 earnings at $15.41 EPS.

Icon (NASDAQ:ICLR - Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The medical research company reported $3.19 earnings per share for the quarter, beating the consensus estimate of $3.17 by $0.02. Icon had a return on equity of 11.46% and a net margin of 9.25%. The firm had revenue of $2 billion during the quarter, compared to the consensus estimate of $2.03 billion. During the same period in the previous year, the company posted $3.47 earnings per share. The firm's quarterly revenue was down 4.3% on a year-over-year basis.

Other research analysts also recently issued research reports about the stock. The Goldman Sachs Group cut their price objective on shares of Icon from $180.00 to $160.00 and set a "neutral" rating on the stock in a research report on Friday, May 2nd. Mizuho dropped their target price on Icon from $200.00 to $173.00 and set an "outperform" rating on the stock in a research report on Thursday, May 15th. TD Cowen lowered Icon from a "buy" rating to a "hold" rating and reduced their price objective for the company from $254.00 to $157.00 in a research note on Monday, April 14th. Robert W. Baird decreased their target price on shares of Icon from $192.00 to $160.00 and set a "neutral" rating for the company in a research note on Friday, May 2nd. Finally, Truist Financial dropped their price objective on Icon from $262.00 to $208.00 and set a "buy" rating on the stock in a report on Thursday, April 10th. Eight investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $198.08.

Icon Stock Down 1.0%

Shares of NASDAQ:ICLR traded down $1.55 on Friday, reaching $150.52. The company had a trading volume of 1,009,179 shares, compared to its average volume of 1,113,400. The firm's 50 day simple moving average is $140.25 and its 200-day simple moving average is $167.99. Icon has a 52-week low of $125.10 and a 52-week high of $347.72. The company has a current ratio of 1.27, a quick ratio of 1.27 and a debt-to-equity ratio of 0.36. The firm has a market capitalization of $12.16 billion, a PE ratio of 16.40, a PEG ratio of 1.86 and a beta of 1.17.

Hedge Funds Weigh In On Icon

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ICLR. SVB Wealth LLC purchased a new stake in shares of Icon in the 1st quarter valued at approximately $28,000. NBC Securities Inc. acquired a new position in shares of Icon in the first quarter valued at approximately $59,000. Bruce G. Allen Investments LLC grew its holdings in shares of Icon by 1,772.7% in the second quarter. Bruce G. Allen Investments LLC now owns 412 shares of the medical research company's stock valued at $60,000 after purchasing an additional 390 shares in the last quarter. Greykasell Wealth Strategies Inc. purchased a new stake in shares of Icon during the first quarter worth $69,000. Finally, Farther Finance Advisors LLC raised its stake in shares of Icon by 22.8% in the first quarter. Farther Finance Advisors LLC now owns 593 shares of the medical research company's stock valued at $99,000 after acquiring an additional 110 shares in the last quarter. Institutional investors and hedge funds own 95.61% of the company's stock.

Icon Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.